Stem Cells for Erectile Dysfunction Post RALP

This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.

Trial Details

NCT ID
NCT07048314
Phase
PHASE1 / PHASE2
Sponsor
The Methodist Hospital Research Institute
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office
  • Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR
  • Placebo in the OR
  • Placebo in clinic
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients scheduled for RALP with Dr. B. Miles at Houston Methodist.
  • Men aged between 40 and 70 (inclusive) years old
  • Localized prostate cancer: Clinical stage T1-T2, N0, M0
  • Gleason score \< 7

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →